The Lancet TheLancet
3 years 5 months ago
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Angus Worthing MD AngusWorthing
3 years 5 months ago
Congrats to Dr @DrDavidKarp on your installation as president of @ACRheum and thanks Dr Ellen Gravallese outgoing president on your outstanding leadership in this year! #ACR20 https://t.co/q0r5URWrEr
Chris Wincup chriswincup
3 years 5 months ago
There are a number of important mimics of IgG4-RD that should be considered
🔵ANCA-associated vasculitis
🔵Multicentric Castleman’s disease
🔵Rosai-Dorfman disease
🔵Inflammatory myofibroblastic tumour
🔵Cutaneous plasmacytosis
🔵Erdheim-Chester disease
🔵Malignancy
#ACR20
Dr. John Cush RheumNow
3 years 5 months ago
Check out our article titled Undifferentiated Autoinflammatory Syndrome Called VEXAS by @RheumNow. We recap Saturday's session on autoinflammatory syndromes featuring Dr. Dan Kastner. #ACR20
https://t.co/afNK3UuZef https://t.co/qGvC2ylmjL
With broader awareness about the disease state, early diagnosis and treatment in autoinflammatory syndromes, and its life threatening complication Macrophage Activation Syndrome, remains a huge unmet need.
The Virtual Classroom Panel: Impact on Medical Education
Panelists Dr. Sheila Reyes, Dr. Karina Torralba, Dr. Anisha Dua, and Dr. Jeffrey Sparks discuss medical education in a virtual environment at the ACR 2020 annual meeting.
Dr. John Cush RheumNow
3 years 5 months ago
Want the highlights of #ACR20 Day 4? Check out our podcast through the link below or through Apple and Android podcasts. Just look up "Rheum Now".
https://t.co/EHcrkIxAez https://t.co/K2pzQPcgdB
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovascular (CV) death in patients with preexisting CV disease.
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Dr. John Cush RheumNow
3 years 5 months ago
The folly of dietary restriction in contemporary gout? by @RichardPAConway
Dr. Conway discusses the abstracts presented at #ACR20
https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS
Dr. John Cush RheumNow
3 years 5 months ago
Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey )
COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20
https://t.co/T2iUwE7XUo https://t.co/AyQ6X2fOJA
New ACR RA Guidelines and Practice Changing Abstracts: RA Panel
Dr. Jonathan Kay leads an international panel on the new ACR RA guidelines and other practice-changing abstracts presented at the 2020 ACR annual meeting. Panelists include Dr.Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.
Dr. John Cush RheumNow
3 years 5 months ago
Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks
https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc
COVID: DMARDs, Steroids, a Vaccine - and how long will this continue? Dr. Winthrop Discusses
Dr. Kevin Winthrop reviews all things COVID-related including abstract L01, steroids and DMARDs, vaccination status - and how long this pandemic will last.
Cardiovascular Risk on MTX in Rheumatoid Arthritis: Dr. Jonathan Kay
Dr. Jonathan Kay reviews several studies that look at the cardiovascular risk of methotrexate in people with rheumatoid arthritis.
Poster Hall